The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 12, 2020

Filed:

Nov. 07, 2019
Applicant:

Daiichi Sankyo Company, Limited, Chuo-ku, Tokyo, JP;

Inventors:

Ryuta Mukasa, Taito-ku, JP;

Kensuke Nakamura, Bunkyo-ku, JP;

Sumie Muramatsu, Sumida-ku, JP;

Naoyuki Makita, Nishinomiya, JP;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61P 1/04 (2006.01); A61P 31/00 (2006.01); A61P 7/06 (2006.01); A61P 43/00 (2006.01); A61P 17/06 (2006.01); A61P 17/00 (2006.01); A61P 37/02 (2006.01); A61P 35/00 (2006.01); A61P 27/02 (2006.01); A61P 19/02 (2006.01); C07K 16/46 (2006.01); A61P 5/16 (2006.01); A61P 37/08 (2006.01); A61P 29/00 (2006.01); C12N 15/09 (2006.01); A61P 21/04 (2006.01); A61P 37/06 (2006.01); A61K 31/56 (2006.01); A61K 45/00 (2006.01); A61P 21/00 (2006.01); A61P 7/04 (2006.01); C12N 5/10 (2006.01); A61P 3/10 (2006.01); A61P 25/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2803 (2013.01); A61K 31/56 (2013.01); A61K 39/395 (2013.01); A61K 45/00 (2013.01); A61P 1/04 (2018.01); A61P 3/10 (2018.01); A61P 5/16 (2018.01); A61P 7/04 (2018.01); A61P 7/06 (2018.01); A61P 17/00 (2018.01); A61P 17/06 (2018.01); A61P 19/02 (2018.01); A61P 21/00 (2018.01); A61P 21/04 (2018.01); A61P 25/00 (2018.01); A61P 27/02 (2018.01); A61P 29/00 (2018.01); A61P 31/00 (2018.01); A61P 35/00 (2018.01); A61P 37/02 (2018.01); A61P 37/06 (2018.01); A61P 37/08 (2018.01); A61P 43/00 (2018.01); C07K 16/28 (2013.01); C07K 16/46 (2013.01); C12N 5/10 (2013.01); C12N 15/09 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/41 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract

To provide a novel antibody. Provided is a monoclonal antibody or a binding fragment thereof that binds to domain 3 of human LAG-3 and has one or more of the properties described in (ii) to (v), and the properties described in (i) and (vi) below: (i) having in vitro ADCC activity; (ii) reducing the number of LAG-3 positive cells in vivo in low fucose form; (iii) suppressing experimental autoimmune encephalomyelitis in vivo in low fucose form; (iv) binding to human activated T cells; (v) human LAG-3 binds to human major histocompatibility complex class II molecules in the presence of the antibody or the binding fragment thereof; and (vi) the presence of the antibody or the binding fragment thereof allowing human LAG-3 to exert a human T cell suppression function.


Find Patent Forward Citations

Loading…